Advertisement


Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

2024 ASCO Annual Meeting

Advertisement

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At the ASCO meeting, we presented data on Network meta-analysis comparing the efficacy of covalent BTK inhibitors for treatment of relapsed refractory CLL. As the background, there are three covalent BTK inhibitors currently approved for CLL, and we do have some randomized trials comparing some of these drugs. For example, acalabrutinib was compared to ibrutinib in the relapse setting in Elevate RR study, and zanubrutinib was compared to ibrutinib in the Alpine trial. However, we don't have a comparison between the two second-generation covalent BTK inhibitors, zanubrutinib and acalabrutinib. There has been an effort recently to indirectly compare the efficacy of this drug through methods like matching adjusted indirect comparison or MAIC. Here we are using another methodology for this indirect comparison called Network meta-analysis, and this is a technique that gives us the opportunity of comparing multiple interventions and use both direct and indirect comparisons. So here we use three clinical trials after going through the inclusion criteria for different trials, and we used Alpine, which compared zanubrutinib versus ibrutinib. We used Elevate RR, which compared acalabrutinib versus ibrutinib, and we also used Ascend trial which compared acalabrutinib versus chemotherapy. And the findings were summarized and in brief, when we looked at the overall response, zanubrutinib was superior to ibrutinib in terms of overall response, the CR rate was not as statistically significant. Also in terms of the overall response and CR rate comparison between zanubrutinib and ibrutinib while there was a trend in favor of zanubrutinib this was not as statistically significant. We also looked at progression free survival, and we did it by adjusting for COVID-19 and also presented the unadjusted comparison. So in the high risk population defined by each clinical trial, zanubrutinib was found to be superior to both ibrutinib and acalabrutinib and also chemo immunotherapy through this PFS analysis. And that was true whether or not we adjusted for COVID-19 or not. When we limited the analysis to only patients with del(17p), zanubrutinib remained superior to ibrutinib and chemo immunotherapy. And also zanubrutinib in the adjusted analysis, but on the unadjusted analysis there was no statistically difference between zanubrutinib and acalabrutinib. And we also looked at overall survival. And while there was a trend in favor of zanubrutinib, this was not a statistically significant. So overall, this is an important study in providing another piece of data and evidence for both clinicians and investigators to put it next to the other analysis that we have recently done and others have done. I would like to remind ourselves that the gold standard remains to be randomized to have clinical trials, and in the absence of direct comparison, we can use methods like MAIC or MET Network meta-analysis to give us a better understanding of the efficacy.

Related Videos

Skin Cancer

Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).

Breast Cancer

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them to enhance survival and quality of life.

Multiple Myeloma

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Multiple Myeloma

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).

Advertisement

Advertisement




Advertisement